|Application ||WB, IHC-P, E|
|Calculated MW||28766 Da|
|Antigen Region||12-41 aa|
|Other Names||Phosphoglycerate mutase 2, BPG-dependent PGAM 2, Muscle-specific phosphoglycerate mutase, Phosphoglycerate mutase isozyme M, PGAM-M, PGAM2, PGAMM|
|Target/Specificity||This PGAM2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 12-41 amino acids from the N-terminal region of human PGAM2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||PGAM2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Interconversion of 3- and 2-phosphoglycerate with 2,3- bisphosphoglycerate as the primer of the reaction. Can also catalyze the reaction of EC 22.214.171.124 (synthase), but with a reduced activity.|
|Tissue Location||Expressed in the heart and muscle. Not found in the liver and brain.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Phosphoglycerate mutase (PGAM) catalyzes the reversible reaction of 3-phosphoglycerate (3-PGA) to 2-phosphoglycerate (2-PGA) in the glycolytic pathway. The PGAM is a dimeric enzyme containing, in different tissues, different proportions of a slow-migrating muscle (MM) isozyme, a fast-migrating brain (BB) isozyme, and a hybrid form (MB). PGAM2 encodes muscle-specific PGAM subunit. Mutations in this gene cause muscle phosphoglycerate mutase eficiency, also known as glycogen storage disease X.
Hadjigeorgiou, G.M., et al. Neuromuscul. Disord. 9 (6-7), 399-402 (1999) :
Tsujino, S., et al. Am. J. Hum. Genet. 52(3):472-477(1993)
Castella-Escola, J., et al. Gene 91(2):225-232(1990)
Castella-Escola, J., et al. Hum. Genet. 84(2):210-212(1990)
Tsujino, S., et al. J. Biol. Chem. 264(26):15334-15337(1989)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.